Fertility Preservation in Adult Male Cancer Patients

  • Robert E. Brannigan
Part of the Cancer Treatment and Research book series (CTAR, volume 138)

Cancer is one of the most common disease states, with approximately 50% of men facing this diagnosis during the course of their lifetime. While the overriding focus for both health care professionals and patients has long been disease cure and survival, a number of factors have led to a significant change in this therapeutic perspective. With marked advances in early disease detection and therapy, patient survival for many cancers has increased dramatically over the last several decades. This, in turn, has provided many patients with the opportunity to live full lives beyond their diagnosis, allowing them to look past their cancer and consider life after treatment. Issues such as post-treatment marriage and parenthood are considered as important as the underlying disease by many patients. As such, measures to preserve sexual and reproductive health in the course of cancer treatment are increasingly important to many patients as they face a malignancy diagnosis.


Leydig Cell Testicular Cancer Sperm Concentration Fertility Preservation Luteinizing Hormone Level 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Meirow D, Schenker JG. Cancer and male infertility. Hum Reprod 1995;10:2017–2022.PubMedGoogle Scholar
  2. 2.
    Hallak J, Kolettis PN, Sekhon VS, et al. Sperm cryopreservation in patients with testicular cancer. Urology 1999;54:894–899.CrossRefPubMedGoogle Scholar
  3. 3.
    Carroll PR, Whitmore WF, Jr., Herr HW, et al. Endocrine and exocrine profiles of men with testicular tumors before orchiectomy. J Urol 1987;137:420–423.PubMedGoogle Scholar
  4. 4.
    Hansen PV, Trykker H, Andersen J, et al. Germ cell function and hormonal status in patients with testicular cancer. Cancer 1989;64:956–961.CrossRefPubMedGoogle Scholar
  5. 5.
    Cochran JS, Walsh PC, Porter JC, et al. The endocrinology of human chorionic gonadotropin-secreting testicular tumors: new methods in diagnosis. J Urol 1975;114:549–555.PubMedGoogle Scholar
  6. 6.
    Aiginger P, Kolbe H, Kuhbock J, et al. The endocrinology of testicular germinal cell tumors. Acta Endocrinol (Copenh) 1981;97:419–426.Google Scholar
  7. 7.
    Turrin NP, Ilyin SE, Gayle DA, et al. Interleukin-1beta system in anorectic catabolic tumor-bearing rats. Curr Opin Clin Nutr Metab Care 2004;7:419–426.CrossRefPubMedGoogle Scholar
  8. 8.
    Ramos EJ, Suzuki S, Marks D, et al. Cancer anorexia-cachexia syndrome: cytokines and neuropeptides. Curr Opin Clin Nutr Metab Care 2004;7:427–434.CrossRefPubMedGoogle Scholar
  9. 9.
    Inui A. Cancer anorexia-cachexia syndrome: are neuropeptides the key? Cancer Res 1999;59:4493–4501.PubMedGoogle Scholar
  10. 10.
    Parker C, Milosevic M, Panzarella T, et al. The prognostic significance of the tumour infiltrating lymphocyte count in stage I testicular seminoma managed by surveillance. Eur J Cancer 2002;38:2014–2019.PubMedGoogle Scholar
  11. 11.
    Rival C, Theas MS, Guazzone VA, et al. Interleukin-6 and IL-6 receptor cell expression in testis of rats with autoimmune orchitis. J Reprod Immunol 2006;70:43–58.CrossRefPubMedGoogle Scholar
  12. 12.
    Theas MS, Rival C, Dietrich SJ, et al. Death receptor and mitochondrial pathways are involved in germ cell apoptosis in an experimental model of autoimmune orchitis. Hum Reprod 2006;21:1734–1742.CrossRefPubMedGoogle Scholar
  13. 13.
    Aitken RJ, Sawyer D. The human spermatozoon–not waving but drowning. Adv Exp Med Biol 2003;518:85–98.PubMedGoogle Scholar
  14. 14.
    Martinez P, Proverbio F, Camejo MI. Sperm lipid peroxidation and pro-inflammatory cytokines. Asian J Androl 2007;9:102–107.CrossRefPubMedGoogle Scholar
  15. 15.
    Guazzieri S, Lembo A, Ferro G, et al. Sperm antibodies and infertility in patients with testicular cancer. Urology 1985;26:139–142.CrossRefPubMedGoogle Scholar
  16. 16.
    Sher KS, Jayanthi V, Probert CS, et al. Infertility, obstetric and gynaecological problems in coeliac sprue. Dig Dis 1994;12:186–190.CrossRefPubMedGoogle Scholar
  17. 17.
    Heyns CF, Fisher M. The urological management of the patient with acquired immunodeficiency syndrome. BJU Int 2005;95:709–716.CrossRefPubMedGoogle Scholar
  18. 18.
    Viviani S, Ragni G, Santoro A, et al. Testicular dysfunction in Hodgkin’s disease before and after treatment. Eur J Cancer 1991;27:1389–1392.CrossRefPubMedGoogle Scholar
  19. 19.
    Berthelsen JG, Skakkebaek NE. Gonadal function in men with testis cancer. Fertil Steril 1983;39:68–75.PubMedGoogle Scholar
  20. 20.
    Morrish DW, Venner PM, Siy O, et al. Mechanisms of endocrine dysfunction in patients with testicular cancer. J Natl Cancer Inst 1990;82:412–418.CrossRefPubMedGoogle Scholar
  21. 21.
    Strasser F, Palmer JL, Schover LR, et al. The impact of hypogonadism and autonomic dysfunction on fatigue, emotional function, and sexual desire in male patients with advanced cancer: a pilot study. Cancer 2006;107:2949–2957.CrossRefPubMedGoogle Scholar
  22. 22.
    Marmor D, Elefant E, Dauchez C, et al. Semen analysis in Hodgkin’s disease before the onset of treatment. Cancer 1986;57:1986–1987.CrossRefPubMedGoogle Scholar
  23. 23.
    Arai Y, Kawakita M, Okada Y, et al. Sexuality and fertility in long-term survivors of testicular cancer. J Clin Oncol 1997;15:1444–1448.PubMedGoogle Scholar
  24. 24.
    Mazeron JJ, Gerbaulet A. [The centenary of the discovery of radium]. Cancer Radiother 1999;3:19–29.PubMedGoogle Scholar
  25. 25.
    Shalet SM. Effect of irradiation treatment on gonadal function in men treated for germ cell cancer. Eur Urol 1993;23:148–151; discussion 152.Google Scholar
  26. 26.
    Hansen PV, Trykker H, Svennekjaer IL, et al. Long-term recovery of spermatogenesis after radiotherapy in patients with testicular cancer. Radiother Oncol 1990;18:117–125.CrossRefPubMedGoogle Scholar
  27. 27.
    Gordon W, Jr., Siegmund K, Stanisic TH, et al. A study of reproductive function in patients with seminoma treated with radiotherapy and orchiectomy: (SWOG-8711). Southwest Oncology Group. Int J Radiat Oncol Biol Phys 1997;38:83–94.PubMedGoogle Scholar
  28. 28.
    Rowley MJ, Leach DR, Warner GA, et al. Effect of graded doses of ionizing radiation on the human testis. Radiat Res 1974;59:665–678.CrossRefPubMedGoogle Scholar
  29. 29.
    Giwercman A, von der Maase H, Berthelsen JG, et al. Localized irradiation of testes with carcinoma in situ: effects on Leydig cell function and eradication of malignant germ cells in 20 patients. J Clin Endocrinol Metab 1991;73:596–603.CrossRefPubMedGoogle Scholar
  30. 30.
    Budgell GJ, Cowan RA, Hounsell AR. Prediction of scattered dose to the testes in abdominopelvic radiotherapy. Clin Oncol 2001;13:120–125.Google Scholar
  31. 31.
    Hermann RM, Henkel K, Christiansen H, et al. Testicular dose and hormonal changes after radiotherapy of rectal cancer. Radiother Oncol 2005;75:83–88.CrossRefPubMedGoogle Scholar
  32. 32.
    Stahl O, Eberhard J, Jepson K, et al. The impact of testicular carcinoma and its treatment on sperm DNA integrity. Cancer 2004;100:1137–1144.CrossRefPubMedGoogle Scholar
  33. 33.
    Thomson AB, Campbell AJ, Irvine DC, et al. Semen quality and spermatozoal DNA integrity in survivors of childhood cancer: a case-control study. Lancet 2002;360:361–367.CrossRefPubMedGoogle Scholar
  34. 34.
    Chatterjee R, Haines GA, Perera DM, et al. Testicular and sperm DNA damage after treatment with fludarabine for chronic lymphocytic leukaemia. Hum Reprod 2000;15:762–766.CrossRefPubMedGoogle Scholar
  35. 35.
    Li FP, Fine W, Jaffe N, et al. Offspring of patients treated for cancer in childhood. J Natl Cancer Inst 1979;62:1193–1197.PubMedGoogle Scholar
  36. 36.
    Hawkins MM, Smith RA, Curtice LJ. Childhood cancer survivors and their offspring studied through a postal survey of general practitioners: preliminary results. J R Coll Gen Pract 1988;38:102–105.PubMedGoogle Scholar
  37. 37.
    Daniell HW, Clark JC, Pereira SE, et al. Hypogonadism following prostate-bed radiation therapy for prostate carcinoma. Cancer 2001;91:1889–1895.CrossRefPubMedGoogle Scholar
  38. 38.
    Mydlo JH, Lebed B. Does brachytherapy of the prostate affect sperm quality and/or fertility in younger men? Scand J Urol Nephrol 2004;38:221–224.CrossRefPubMedGoogle Scholar
  39. 39.
    Grocela J, Mauceri T, Zietman A. New life after prostate brachytherapy? Considering the fertile female partner of the brachytherapy patient. BJU Int 2005;96:781–782.CrossRefPubMedGoogle Scholar
  40. 40.
    Jacobsen KD, Olsen DR, Fossa K, et al. External beam abdominal radiotherapy in patients with seminoma stage I: field type, testicular dose, and spermatogenesis. Int J Radiat Oncol Biol Phys 1997;38:95–102.PubMedGoogle Scholar
  41. 41.
    Aass N, Fossa SD, Theodorsen L, et al. Prediction of long-term gonadal toxicity after standard treatment for testicular cancer. Eur J Cancer 1991;27:1087–1091.CrossRefPubMedGoogle Scholar
  42. 42.
    Huyghe E, Matsuda T, Daudin M, et al. Fertility after testicular cancer treatments: results of a large multicenter study. Cancer 2004;100:732–737.CrossRefPubMedGoogle Scholar
  43. 43.
    Huddart RA, Norman A, Moynihan C, et al. Fertility, gonadal and sexual function in survivors of testicular cancer. Br J Cancer 2005;93:200–207.CrossRefPubMedGoogle Scholar
  44. 44.
    Kinsella TJ, Trivette G, Rowland J, et al. Long-term follow-up of testicular function following radiation therapy for early-stage Hodgkin’s disease. J Clin Oncol 1989;7:718–724.PubMedGoogle Scholar
  45. 45.
    Socie G, Salooja N, Cohen A, et al. Nonmalignant late effects after allogeneic stem cell transplantation. Blood 2003;101:3373–3385.CrossRefPubMedGoogle Scholar
  46. 46.
    Sanders JE, Hawley J, Levy W, et al. Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation. Blood 1996;87:3045–3052.PubMedGoogle Scholar
  47. 47.
    Salooja N, Szydlo RM, Socie G, et al. Pregnancy outcomes after peripheral blood or bone marrow transplantation: a retrospective survey. Lancet 2001;358:271–276.CrossRefPubMedGoogle Scholar
  48. 48.
    Spitz S. The histological effects of nitrogen mustard on human tumours and tissues. Cancer 1948;383–398.Google Scholar
  49. 49.
    Witt KL, Bishop JB. Mutagenicity of anticancer drugs in mammalian germ cells. Mutat Res 1996;355:209–234.PubMedGoogle Scholar
  50. 50.
    Byrne J, Mulvihill JJ, Myers MH, et al. Effects of treatment on fertility in long-term survivors of childhood or adolescent cancer. N Engl J Med 1987;317:1315–1321.PubMedCrossRefGoogle Scholar
  51. 51.
    Buchanan JD, Fairley KF, Barrie JU. Return of spermatogenesis after stopping cyclophosphamide therapy. Lancet 1975;2:156–157.CrossRefPubMedGoogle Scholar
  52. 52.
    Bokemeyer C, Schmoll HJ, van Rhee J, et al. Long-term gonadal toxicity after therapy for Hodgkin’s and non-Hodgkin’s lymphoma. Ann Hematol 1994;68:105–110.CrossRefPubMedGoogle Scholar
  53. 53.
    Choudhury RC, Misra S, Jagdale MB, et al. Induction and transmission of cytogenetic toxic effects of 5-fluorouracil in male germline cells of Swiss mice. J Exp Clin Cancer Res 2002;21:277–282.PubMedGoogle Scholar
  54. 54.
    D’Souza UJ, Narayana K. Induction of seminiferous tubular atrophy by single dose of 5-fluorouracil (5-FU) in Wistar rats. Indian J Physiol Pharmacol 2001;45:87–94.PubMedGoogle Scholar
  55. 55.
    D’Souza UJ. Re: 5-Fluorouracil-induced sperm shape abnormalities in rats. Asian J Androl 2003;5:353.PubMedGoogle Scholar
  56. 56.
    Choudhury RC, Jagdale MB, Misra S. Potential transmission of the cytogenetic effects of cisplatin in the male germline cells of Swiss mice. J Chemother 2000;12:352–359.PubMedGoogle Scholar
  57. 57.
    Lampe H, Horwich A, Norman A, et al. Fertility after chemotherapy for testicular germ cell cancers. J Clin Oncol 1997;15:239–245.PubMedGoogle Scholar
  58. 58.
    Arnon J, Meirow D, Lewis-Roness H, et al. Genetic and teratogenic effects of cancer treatments on gametes and embryos. Hum Reprod Update 2001;7:394–403.CrossRefPubMedGoogle Scholar
  59. 59.
    Sjoblom T, Parvinen M, Lahdetie J. Stage-specific DNA synthesis of rat spermatogenesis as an indicator of genotoxic effects of vinblastine, mitomycin C and ionizing radiation on rat spermatogonia and spermatocytes. Mutat Res 1995;331:181–190.PubMedGoogle Scholar
  60. 60.
    Aubier F, Flamant F, Brauner R, et al. Male gonadal function after chemotherapy for solid tumors in childhood. J Clin Oncol 1989;7:304–309.PubMedGoogle Scholar
  61. 61.
    van Buul PP, Goudzwaard JH. Bleomycin-induced structural chromosomal aberrations in spermatogonia and bone-marrow cells of mice. Mutat Res 1980;69:319–324.PubMedGoogle Scholar
  62. 62.
    Hou M, Chrysis D, Nurmio M, et al. Doxorubicin induces apoptosis in germ line stem cells in the immature rat testis and amifostine cannot protect against this cytotoxicity. Cancer Res 2005;65:9999–10005.CrossRefPubMedGoogle Scholar
  63. 63.
    Foster RS, Bennett R, Bihrle R, et al. A preliminary report: postoperative fertility assessment in nerve-sparing RPLND patients. Eur Urol 1993;23:165–167; discussion 168.Google Scholar
  64. 64.
    Schlegel PN, Walsh PC. Neuroanatomical approach to radical cystoprostatectomy with preservation of sexual function. J Urol 1987;138:1402–1406.PubMedGoogle Scholar
  65. 65.
    Rajagopal A, Vassilopoulou-Sellin R, Palmer JL, et al. Symptomatic hypogonadism in male survivors of cancer with chronic exposure to opioids. Cancer 2004;100:851–858.CrossRefPubMedGoogle Scholar
  66. 66.
    Landis SH, Murray T, Bolden S, et al. Cancer statistics, 1999. CA Cancer J Clin 1999;49:8–31, 1.Google Scholar
  67. 67.
    Sant M, Aareleid T, Berrino F, et al. EUROCARE-3: survival of cancer patients diagnosed 1990–94–results and commentary. Ann Oncol 2003;14 Suppl 5:v61–v118.CrossRefPubMedGoogle Scholar
  68. 68.
    Bleyer WA. The impact of childhood cancer on the United States and the world. CA Cancer J Clin 1990;40:355–367.CrossRefPubMedGoogle Scholar
  69. 69.
    Schover LR, Brey K, Lichtin A, et al. Knowledge and experience regarding cancer, infertility, and sperm banking in younger male survivors. J Clin Oncol 2002;20:1880–1889.CrossRefPubMedGoogle Scholar
  70. 70.
    Living Beyond Cancer: Finding a New Balance, President’s Cancer Panel 2003–2004 Annual Report, U.S. Department of Health and Human Services, 2004, 1–87.Google Scholar
  71. 71.
    Zapzalka DM, Redmon JB, Pryor JL. A survey of oncologists regarding sperm cryopreservation and assisted reproductive techniques for male cancer patients. Cancer 1999;86:1812–1817.CrossRefPubMedGoogle Scholar
  72. 72.
    Lass A, Akagbosu F, Abusheikha N, et al. A programme of semen cryopreservation for patients with malignant disease in a tertiary infertility centre: lessons from 8 years’ experience. Hum Reprod 1998;13:3256–3261.CrossRefPubMedGoogle Scholar
  73. 73.
    Lee SJ, Schover LR, Partridge AH, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006;24:2917–2931.CrossRefPubMedGoogle Scholar
  74. 74.
    Bracken RB, Smith KD. Is semen cryopreservation helpful in testicular cancer? Urology 1980;15:581–583.CrossRefPubMedGoogle Scholar
  75. 75.
    Sanger WG, Armitage JO, Schmidt MA. Feasibility of semen cryopreservation in patients with malignant disease. JAMA 1980;244:789–790.CrossRefPubMedGoogle Scholar
  76. 76.
    Rosenlund B, Westlander G, Wood M, et al. Sperm retrieval and fertilization in repeated percutaneous epididymal sperm aspiration. Hum Reprod 1998;13:2805–2807.CrossRefPubMedGoogle Scholar
  77. 77.
    Res U, Res P, Kastelic D, et al. Birth after treatment of a male with seminoma and azoospermia with cryopreserved-thawed testicular tissue. Hum Reprod 2000;15:861–864.CrossRefPubMedGoogle Scholar
  78. 78.
    Kohn FM, Schroeder-Printzen I, Weidner W, et al. Testicular sperm extraction in a patient with metachronous bilateral testicular cancer. Hum Reprod 2001;16:2343–2346.PubMedGoogle Scholar
  79. 79.
    Schrader M, Muller M, Sofikitis N, et al. “Onco-tese”: testicular sperm extraction in azoospermic cancer patients before chemotherapy-new guidelines? Urology 2003;61:421–425.CrossRefPubMedGoogle Scholar
  80. 80.
    Johnson DH, Linde R, Hainsworth JD, et al. Effect of a luteinizing hormone releasing hormone agonist given during combination chemotherapy on posttherapy fertility in male patients with lymphoma: preliminary observations. Blood 1985;65:832–836.PubMedGoogle Scholar
  81. 81.
    Waxman JH, Ahmed R, Smith D, et al. Failure to preserve fertility in patients with Hodgkin’s disease. Cancer Chemother Pharmacol 1987;19:159–162.CrossRefPubMedGoogle Scholar
  82. 82.
    Brennemann W, Brensing KA, Leipner N, et al. Attempted protection of spermatogenesis from irradiation in patients with seminoma by D-Tryptophan-6 luteinizing hormone releasing hormone. Clin Invest 1994;72:838–842.CrossRefGoogle Scholar
  83. 83.
    Kreuser ED, Hetzel WD, Hautmann R, et al. Reproductive toxicity with and without LHRHA administration during adjuvant chemotherapy in patients with germ cell tumors. Horm Metab Res 1990;22:494–498.CrossRefPubMedGoogle Scholar
  84. 84.
    Brook PF, Radford JA, Shalet SM, et al. Isolation of germ cells from human testicular tissue for low temperature storage and autotransplantation. Fertil Steril 2001;75:269–274.CrossRefPubMedGoogle Scholar
  85. 85.
    Nagano M, Patrizio P, Brinster RL. Long-term survival of human spermatogonial stem cells in mouse testes. Fertil Steril 2002;78:1225–1233.CrossRefPubMedGoogle Scholar
  86. 86.
    Schlatt S, Honaramooz A, Ehmcke J, et al. Limited survival of adult human testicular tissue as ectopic xenograft. Hum Reprod 2006;21:384–389.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Robert E. Brannigan
    • 1
  1. 1.Northwestern UniversityChicagoUSA

Personalised recommendations